Askari Arman T., Lincoff A. Michael (eds.) Antithrombotic Drug Therapy in Cardiovascular Disease

Humana Press, 2010. — 463 p. — ISBN: 978-1-60327-234-6Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT).Basic Principles
Platelets in Arterial Thrombosis
The Role of Coagulation in Arterial and Venous Thrombosis
The Link Between Inflammation and Thrombosis
The Genetics of Thrombosis
Antithrombotic Therapy for Stable Coronary Atherosclerotic Disease
Aspirin in Primary and Secondary Prevention of Cardiovascular Disease
Thienopyridines in Stable Coronary Disease
Antithrombotic Therapy for NSTE ACS
Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction
Unfractionated Heparin and Enoxaparin for the Management of Non-ST-Segment Elevation Acute Coronary Syndromes
Direct Thrombin Inhibitors in Acute Coronary Syndromes
Synthetic Factor Xa Inhibition in Acute Coronary Syndromes
Antithrombotic Therapy for STEMI
Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction
Antithrombin Therapy for Acute ST-Segment Elevation Myocardial Infarction
Fibrinolysis and Facilitated PCI
Antithrombotic Therapy in Interventional Cardiology
Antithrombotic Therapy in Percutaneous Coronary Intervention
Antithrombotic Therapy in Carotid and Peripheral Intervention
Monitoring of Antithrombotic Therapies in Interventional Cardiology
Antithrombotic Therapy in Venous Thromboembolism
Venous Thromboembolism
Fibrinolysis for Pulmonary Embolism
Duration of Anticoagulant Therapy After Venous Thromboembolism
Clinical Consideration
Antithrombotic Therapy for Atrial Fibrillation and Cardioversion
Antithrombotic Therapy for Valvular Heart Disease
Antithrombotic Therapy in Heart Failure and Cardiomyopathy
Heparin-Induced Thrombocytopenia
Resistance to Antiplatelet Drugs